4,595 results match your criteria Am. J. Clin. Oncol.[Journal]


Analysis of Outcomes in Patients With BRCA1/2 Breast Cancer Mutations Treated With Accelerated Partial Breast Irradiation (APBI).

Am J Clin Oncol 2019 Apr 9. Epub 2019 Apr 9.

Departments of Radiation Oncology.

Objective: To analyze outcomes and survival for BRCA1/2+ patients treated with accelerated partial breast irradiation (APBI).

Materials And Methods: Retrospective review was performed on 341 women treated with intracavitary APBI (Mammosite or Contura) postlumpectomy from 2002 to 2013. Patients were treated to 34. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000542DOI Listing

Phase I Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) in Combination With Selective VEGFR Inhibitor Pazopanib for Therapy of Advanced Solid Tumors.

Am J Clin Oncol 2019 Apr 9. Epub 2019 Apr 9.

Department of Medicine, Division of Hematology/Oncology.

Objectives: Pazopanib is a multikinase angiogenesis inhibitor. Alisertib is a highly selective inhibitor of mitotic Aurora A kinase. There is preclinical evidence that mitosis-targeting agents exhibit antiangiogenic effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000543DOI Listing

Rapid Early Tumor Progression is Prognostic in Glioblastoma Patients.

Am J Clin Oncol 2019 Apr 9. Epub 2019 Apr 9.

Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA.

Objectives: Determine the prognostic significance of rapid early tumor progression before radiation and chemotherapy for glioblastoma patients.

Methods: A retrospective review of glioblastoma patients was performed. Rapid early progression (REP) was defined as new enhancing tumor or >25% increase in enhancement before radiotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000537DOI Listing
April 2019
1 Read

Uterine Papillary Serous Carcinoma Arising in a Polyp: A Multicenter Retrospective Analysis on 75 Patients.

Am J Clin Oncol 2019 Apr 9. Epub 2019 Apr 9.

Unit of Obstetrics and Gynecology, Azienda USL-IRCCS of Reggio Emilia.

Objectives: The objectives of this study were to evaluate whether the international recommendations on the management of uterine papillary serous carcinoma arising in a polyp are uniformly followed in Italian Oncologic Centers and whether the strategy adopted is effective.

Materials And Methods: Patients with uterine papillary serous carcinoma arising in a polyp and who had undergone a hysterectomy were identified in the 2003-2013 database of 7 Italian Gynecologic Oncology Centers. Clinical and pathologic characteristics and outcomes were compared between staging procedure types. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000541DOI Listing
April 2019
1 Read

Conditional Survival Analysis of Metastatic Colorectal Cancer Patients Living ≥24 Months: A Single Institutional Study.

Am J Clin Oncol 2019 Apr 9. Epub 2019 Apr 9.

Departments of Surgery.

Objectives: The survival of patients with metastatic colorectal cancer (CRC) has been increasing over recent decades due to improvements in chemotherapy and surgery. There is a need to refine prognostic information to more accurately predict survival as patients survive for any given length of time to assist multidisciplinary cancer management teams in treatment decisions.

Materials And Methods: We performed a single center retrospective analysis of patients treated with metastatic CRC (unresectable and resectable) who survived >24 months between 2005 and 2015 (N=155). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000535DOI Listing
April 2019
6 Reads

Epidemiology, Tumor Characteristics, and Survival in Patients With Primary Pancreatic Lymphoma: A Large Population-based Study Using the SEER Database.

Am J Clin Oncol 2019 Apr 3. Epub 2019 Apr 3.

Department of Hematology and Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH.

Introduction: Primary pancreatic lymphoma (PPL) is an extranodal manifestation of non-Hodgkin lymphoma originating in the pancreas, which constitutes <1% of all pancreatic neoplasms. Because of the rarity of the disease, most data on PPL are derived from case reports and small case series. To provide better insight into the epidemiology, treatment, and outcomes of these patients, we conducted an analysis of patients with PPL from the Surveillance, Epidemiology and End Results (SEER) database, which is presented in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000544DOI Listing
April 2019
3 Reads

Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy: A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTONG1304).

Am J Clin Oncol 2019 Apr 3. Epub 2019 Apr 3.

IMED Asia, AstraZeneca.

Objective: There is no standard care for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation in the third line. Our study aimed to assess the efficacy and safety of gefitinib as a third-line re-challenge treatment for advanced NSCLC patients with EGFR mutation.

Materials And Methods: It was a multicenter, open-label, single-arm, phase II study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000538DOI Listing
April 2019
3 Reads

Atypical Lipomatous Tumors: Does Our Inconsistent Terminology Have Patient Repercussions? Results of a Meta-Analysis.

Am J Clin Oncol 2019 Mar 29. Epub 2019 Mar 29.

Department of Orthopaedic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.

Objectives: Misnaming low-grade lipomatous tumors poses a clinical and medicolegal challenge, potentially subjecting patients to expensive and unnecessary surgeries. The terms atypical lipomatous tumor (ALT) and "well-differentiated" liposarcoma (WDL) have been used interchangeably in pathology reports, scholarly works and consensus recommendations, creating vagaries between low-virulence extremity tumors and retroperitoneal disease with metastatic potential.

Methods: A systematic review was performed on all studies that reported on the local recurrence rate and metastasis of ALTs and WDLs in living human subjects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000540DOI Listing
March 2019
1 Read

Pathologic Response to Neoadjuvant Therapy is Associated With Improved Long-term Survival in High-risk Primary Localized Malignant Peripheral Nerve Sheath Tumors.

Am J Clin Oncol 2019 Mar 25. Epub 2019 Mar 25.

Departments of Surgery, Division of Surgical Oncology.

Background: Malignant peripheral nerve sheath tumors (MPNSTs) comprise a rare, aggressive subtype of soft tissue sarcoma. While surgery is the mainstay of therapy for this disease, the role of neoadjuvant therapy remains undefined.

Methods: This study reviewed patients 16 years of age and older who underwent surgical treatment for MPNST between 1974 and 2012 at the authors' institution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000536DOI Listing

Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysis.

Am J Clin Oncol 2019 Mar 25. Epub 2019 Mar 25.

London Regional Cancer Program, Department of Oncology, Division of Medical Oncology.

The role of adjuvant tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) is not well defined. Recent randomized controlled trials showed a disease-free survival (DFS) benefit in patients harboring an epidermal growth factor receptor (EGFR) mutation. Yet, older trials on patients with any EGFR status did not demonstrate the same benefit. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000533DOI Listing
March 2019
1 Read

BCLC-B Subclassification and the Hong Kong Liver Cancer System in Intermediate Hepatocellular Carcinoma: Identifying Candidates for Curative Therapy.

Am J Clin Oncol 2019 Mar 25. Epub 2019 Mar 25.

Graduate Program in Gastroenterology and Hepatology.

Introduction: The intermediate stage of the Barcelona Clinic Liver Cancer (BCLC) classification includes a heterogenous population of patients with hepatocellular carcinoma (HCC), and palliative treatment with transarterial chemoembolization is recommended for all of them. In this regard, 2 other classifications could be useful, the subclassification BCLC-B (SUB) and the classification Hong Kong Liver Cancer (HKLC).

Objective: To determine the indication of curative or palliative treatment between SUB and HKLC in BCLC-B patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000539DOI Listing
March 2019
1 Read

Mohs Micrographic Surgery Volume, Utilization, and Overutilization Based on Medicare Data.

Authors:
Jonathan Kantor

Am J Clin Oncol 2019 Apr;42(4):411-412

Department of Dermatology, University of Pennsylvania Perelman School of Medicine Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000517DOI Listing

Laparoscopic-assisted Versus Open D2 Gastrectomy for Advanced Gastric Cancer in Highly Selective Patients: Short-term Surgical and Chemotherapy Outcomes of a Prospective Cohort Study.

Am J Clin Oncol 2019 Mar 15. Epub 2019 Mar 15.

Department of General Surgery, Qilu Hospital of Shandong University, Jinan, China.

Objectives: The feasibility and efficacy of laparoscopic-assisted D2 gastrectomy (LAD2G) for advanced gastric cancer (AGC) remain controversial. We conducted a prospective cohort study to provide a comprehensive comparison of LAD2G and open D2 gastrectomy (OD2G) for AGC.

Materials And Methods: Between April 2016 and December 2017, patients with clinical stage T2-4aN0-3M0 gastric cancer were enrolled and assigned to either LAD2G or OD2G group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000534DOI Listing

Radiation Treatment for Ewing Sarcoma Family of Tumors in Adult Patients: A Single Institution's Experience Over 40 Years.

Am J Clin Oncol 2019 Mar 15. Epub 2019 Mar 15.

Departments of Radiation Oncology.

Purpose/objectives: To report prognostic factors and long-term outcomes in adults with Ewing sarcoma treated with definitive radiotherapy.

Materials And Methods: We reviewed patients 18 years old and above with nonmetastatic Ewing sarcoma treated with radiotherapy +/- chemotherapy or surgery. Outcomes were stratified by age (30 and above vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000532DOI Listing

Mental Health Disorders are More Common in Colorectal Cancer Survivors and Associated With Decreased Overall Survival.

Am J Clin Oncol 2019 Apr;42(4):355-362

Department of Family and Preventive Medicine, Division of Public Health, Huntsman Cancer Institute, University of Utah School of Medicine.

Objectives: To determine the risk and risk factors for mental illness among colorectal cancer (CRC) survivors across short-term and long-term follow-up periods.

Methods: We used the Utah Cancer Registry to identify CRC survivors diagnosed between 1997 and 2013. Mental health diagnoses were available in electronic medical records and statewide facilities data that were linked by the Utah Population Database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000529DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433523PMC
April 2019
2 Reads

Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection.

Am J Clin Oncol 2019 Apr;42(4):399-406

Duke University School of Medicine, Durham, NC.

Bone metastases are common in men with metastatic castrate-resistant prostate cancer (mCRPC), occurring in 30% of patients within 2 years of castrate resistance and in >90% of patients over the disease course. There are 6 US Food and Drug Administration-approved therapies for mCRPC with demonstrated survival benefit. Of these, only radium-223 (Ra-223) specifically targets bone metastases, delays development of skeletal-related events, and improves survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000528DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445613PMC

Bisphosphonate-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Tumor of Bone: A 1 to 12-Year Follow-up Study.

Am J Clin Oncol 2019 Mar;42(3):231-237

Department of Orthopaedic Surgery, Yale University, New Haven, CT.

Background: Historically, nontargeted adjuvant therapies such as liquid nitrogen, phenol, argon beam, and alcohol have been applied locally after curettage of giant cell tumors (GCT) in the extremities. Systemic bisphosphonates (BP) and denosumab have emerged as osteoclast-targeting therapies because osteoclast-like giant cells, responsible for aggressive bone resorption, are susceptible to BP or denosumab. However, such drugs may cause systemic side effects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000504DOI Listing

Phase IB Study of Induction Chemotherapy With XELOX, Followed by Radiation Therapy, Carboplatin, and Everolimus in Patients With Locally Advanced Esophageal Cancer.

Am J Clin Oncol 2019 Apr;42(4):331-336

Radiation Oncology, Vanderbilt University, Nashville, TN.

Purpose: Preclinical studies have shown synergy between everolimus, an mTOR inhibitor, radiation, and platinum agents. We conducted a phase IB trial to determine the recommended phase II dose of everolimus with carboplatin and radiation.

Materials And Methods: Patients with stage II/III esophageal cancer were enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000524DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433493PMC
April 2019
1 Read

Incidence of Neonatal Neutropenia and Leukopenia After In Utero Exposure to Chemotherapy for Maternal Cancer.

Am J Clin Oncol 2019 Apr;42(4):351-354

Cooper Medical School at Rowan University, Camden, NJ.

Objective: The main purpose of this article was to report the incidence of neonatal neutropenia or leukopenia after chemotherapy exposure during pregnancy according to the time elapsed between treatment during pregnancy and birth.

Background: A single study reports 33% of infants exposed to chemotherapy within the last month of pregnancy are born with neutropenia, which can place the newborn at risk for nosocomial infections. On the basis of this report, chemotherapy is typically stopped by 34 weeks of pregnancy to avoid maternal or neonatal myelosuppression at delivery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000527DOI Listing
April 2019
1 Read

Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E5805).

Am J Clin Oncol 2019 Apr;42(4):375-381

University of Kentucky, Lexington, KY.

Background: Eribulin mesylate, a synthetic analog of halichondrin B, is a novel tubulin-binding agent that inhibits cancer cell proliferation at low-nanomolar levels.

Methods: In a multicenter ECOG trial, patients with progressive metastatic CRPC, ECOG 0-2 were treated with eribulin 1.4 mg/m as an IV bolus over 5 minutes on days 1 and 8 of a 21-day cycle. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000526DOI Listing
April 2019
1 Read

Effects of Social and Contextual Factors Including Marital Status and Children on the Use of Palliative Chemotherapy in Metastatic Colorectal Cancer.

Am J Clin Oncol 2019 Apr;42(4):363-366

Department of Community Health and Epidemiology, University of Saskatchewan, Saskatoon, SK Canada.

Background: There is evidence that social and contextual factors such as living alone are associated with outcomes in cancer patients. However, little is known about their influence on the use of palliative chemotherapy in metastatic colorectal cancer (mCRC). In this study, we examined social and contextual factors, including marital status, having children, and distance to a cancer center, for their association with the use of chemotherapy in patients with mCRC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000530DOI Listing
April 2019
3 Reads

Concurrent Versus Sequential Chemoradiation for Low-grade Gliomas Meeting RTOG 9802 Criteria.

Am J Clin Oncol 2019 Apr;42(4):391-398

Departments of Radiation Oncology.

Purpose: Radiation Therapy Oncology Group (RTOG) 9802 has established postoperative radiation therapy (RT) and chemotherapy sequentially as the new standard of care for patients with high-risk low-grade glioma (LGG) meeting trial criteria. Although this trial investigated sequential chemoradiation therapy (sCRT) with RT followed by chemotherapy, it is unknown whether concurrent chemoradiation therapy (cCRT) may offer advantages over sCRT.

Materials And Methods: The National Cancer Database (NCDB) was queried for newly diagnosed World Health Organization (WHO) grade II glioma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000519DOI Listing
April 2019
2 Reads

Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma.

Am J Clin Oncol 2019 Apr;42(4):337-344

Department of Medical Oncology and Therapeutic Research, City of Hope National Medical Center, Duarte, CA.

Introduction: Anaplastic lymphoma kinase (ALK) gene rearrangements are observed in about 4% to 8% non-small cell lung cancer (NSCLC). ALK+ tumors have been associated with increased pleural and pericardial disease. Our primary objective was to determine the uncommon sites of metastasis of ALK+ NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000508DOI Listing
April 2019
2 Reads

Dual Modality Radiation With External Beam Radiation Therapy and Transarterial Radioembolization for Hepatocellular Carcinoma With Gross Vascular Invasion.

Am J Clin Oncol 2019 Apr;42(4):367-374

Departments of Radiation Oncology.

Objectives: Patients with hepatocellular carcinoma (HCC) and gross vascular invasion (GVI) have poor outcomes with systemic therapy such as sorafenib. Both external beam radiation therapy (EBRT) and transarterial radioembolization (TARE) have been utilized for this patient population. We sought to compare outcomes using dual modality radiation (EBRT+TARE) versus EBRT alone in patients with HCC and GVI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000523DOI Listing
April 2019
1 Read
2.611 Impact Factor

Pattern of Marginal Local Failure in a Phase II Trial of Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy for Resectable and Borderline Resectable Pancreas Cancer.

Am J Clin Oncol 2019 Mar;42(3):247-252

Surgical Oncology.

Objectives: The main objectives of this study were to prospectively evaluate the safety and efficacy of stereotactic body radiation therapy (SBRT) in the neoadjuvant setting for resectable or borderline resectable pancreatic cancer.

Materials And Methods: Eighteen patients were enrolled from November 2014 to June 2017. Following 3 cycles of chemotherapy, SBRT was delivered to the tumor and abutting vessel and a 3 mm planning target volume (PTV) margin to 33 Gy (6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000518DOI Listing
March 2019
2 Reads

Application of a Prognostic Stratification System for High-risk Prostate Cancer to Patients Treated With Radiotherapy: Implications for Treatment Optimization.

Am J Clin Oncol 2019 Apr;42(4):382-390

Department of Radiation Oncology, Beaumont Hospital, Dearborn, MI.

Objectives: We applied an established prognostic model to high-risk prostate cancer (HRPC) patients treated with radiotherapy (RT) and evaluated the influence of clinical and treatment variables on treatment outcomes.

Methods: In total, 1075 HRPC patients undergoing definitive radiotherapy (RT) between 1995 and 2010 were retrospectively reviewed. Median follow-up was 62. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000521DOI Listing
April 2019
4 Reads

Elevated Pretreatment CEA and CA19-9 Levels are Related to Early Treatment Failure in Esophageal Adenocarcinoma.

Am J Clin Oncol 2019 Apr;42(4):345-350

Departments of Surgical Oncology.

Introduction: Chemoradiotherapy and surgery are the basis of the potentially curative treatment for esophageal cancer. Approximately 1 in 5 patients, however, do not benefit from this intensive treatment due to early treatment failure. The aim of this study was to evaluate levels of carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 at diagnosis, in relation to survival and early treatment failure (disease recurrence or death within 1 year after surgery). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000525DOI Listing

Tobacco Treatment Programs at National Cancer Institute-designated Cancer Centers: A Systematic Review and Online Audit.

Am J Clin Oncol 2019 Apr;42(4):407-410

Department of Otolaryngology - Head and Neck Surgery, Johns Hopkins Medical Institutions.

Objectives: The main objectives of this study were to evaluate abstinence rates of tobacco treatment programs (TTPs) at National Cancer Institute (NCI)-designated cancer centers (DCCs) and to ascertain the number of NCI-DCCs with online references to TTPs.

Methods: Literature searches of Pubmed, EMBASE, Web of Science, and Scopus were performed from their inception through January 2018 using keywords including cancer patients, cancer survivors, tobacco, smoking, cessation, and program. In total, 4094 articles were identified, 1450 duplicates were removed, 2644 candidate titles and abstracts were screened, and 210 selected full-text articles were independently reviewed by 2 authors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000522DOI Listing

Reply to Elmali and Colleagues.

Am J Clin Oncol 2019 Feb;42(2):228-229

Department of Radiation Oncology, College of Medicine, University of Florida, Gainesville, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000502DOI Listing
February 2019

A Phase II Study Evaluating Bone Marrow-Sparing, Image-guided Pelvic Intensity-Modulated Radiotherapy (IMRT) With Cesium-131 Brachytherapy Boost, Adjuvant Chemotherapy, and Long-Term Hormonal Ablation in Patients With High Risk, Nonmetastatic Prostate Cancer.

Am J Clin Oncol 2019 Mar;42(3):285-291

Department of Radiation Oncology.

Purpose/objective(s): Management of localized high-risk prostate cancer remains challenging. At our institution we performed a prospective phase II study of 2 years of androgen deprivation therapy (ADT), pelvic radiation, Cesium (Cs)-131 brachytherapy boost, and adjuvant docetaxel in high risk, localized prostate cancer with a primary endpoint of 3-year disease-free survival.

Materials/methods: Acute/chronic hematologic, gastrointestinal (GI) and genitourinary (GU) toxicities were scored based on the CTCAE v3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000520DOI Listing
March 2019
2 Reads

Metformin Use and Kidney Cancer Survival Outcomes: A Systematic Review and Meta-Analysis.

Am J Clin Oncol 2019 Mar;42(3):275-284

Departments of Surgery and Surgical Oncology, Division of Urology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto.

Objectives: Metformin has been associated with improved survival outcomes in various malignancies. However, studies in kidney cancer are conflicting. We performed a systematic review and meta-analysis to evaluate the association between metformin and kidney cancer survival. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00000421-900000000-9884
Publisher Site
http://dx.doi.org/10.1097/COC.0000000000000512DOI Listing
March 2019
10 Reads

Impact of Primary Care Access on Mortality of Lung Cancer Patients in an Underserved Community.

Am J Clin Oncol 2019 Mar;42(3):298-303

Oncology.

Background: Lack of access to primary care physicians (PCPs) may be an important contributor to mortality differences attributed to race/ethnicity. This study examined the effects of primary care access on mortality of lung cancer patients in an underserved community.

Methods: Medical records of all newly diagnosed patients with primary lung cancer from 2012 to 2016 at a National Cancer Institute (NCI)-designated center in Bronx, New York were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000516DOI Listing
March 2019
2 Reads

Effect of Neutropenic Diet on Infection Rates in Cancer Patients With Neutropenia: A Meta-analysis of Randomized Controlled Trials.

Am J Clin Oncol 2019 Mar;42(3):270-274

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore MD.

Introduction: Neutropenic diets are commonly prescribed to cancer patients with neutropenia with the intention of reducing rates of infection. These diets are restrictive and are associated with lower patient satisfaction and possibly malnutrition. Further, it is unclear if these restrictive diets are effective in reducing infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000514DOI Listing
March 2019
29 Reads

Extraskeletal Osteosarcomas: A Case Made for Combined Modality Local Therapy With Radiation and Surgery.

Am J Clin Oncol 2019 Mar;42(3):238-242

Departments of Radiation Oncology.

Objective: We evaluated our experience treating patients with extraskeletal osteosarcoma (ESOS) using combined modality local therapy, including surgery and radiation therapy (RT), to investigate local control (LC) and other survival endpoints.

Methods: We reviewed the records of 21 consecutive patients with nonmetastatic, ESOS treated with RT in combination with surgery at our institution from 1984 to 2015. Postoperative RT was used for 10 patients (48%) to a median dose of 60 Gy (range, 60 to 68 Gy). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000515DOI Listing
March 2019
6 Reads

Survival Implications of De Novo Versus Recurrent Metastatic Non-Small Cell Lung Cancer.

Am J Clin Oncol 2019 Mar;42(3):292-297

Department of Medicine, University of British Columbia.

Objectives: Metastatic non-small cell lung cancer (NSCLC) has a poor prognosis. Most patients present with stage IV, and many patients treated curatively with stage I to III develop recurrent metastatic disease. It is unknown whether the natural history differs between patients with recurrent versus de novo metastatic NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000513DOI Listing
March 2019
28 Reads

Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma With the Introduction of New Chemotherapeutic Drugs: 10-Year Experience of a Single NCI-designated Comprehensive Cancer Center.

Am J Clin Oncol 2019 Mar;42(3):243-246

Department of Oncology, Wayne State University School of Medicine, Barbara Ann Karmanos Cancer Institute, Detroit, MI.

Objectives: Adenocarcinoma of the pancreas represents the third leading cause of cancer-related death in the United States. Drug combinations, FOLFIRINOX (5-FU, leucovorin, irinotecan, and oxaliplatin) and gemcitabine/nab-paclitaxel, showed a clinically meaningful benefit when compared with single-agent gemcitabine in phase III trials. The goal of this study was to investigate whether there was an increase in overall survival (OS) for patients treated for metastatic pancreatic cancer after the introduction of the above regimens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000507DOI Listing
March 2019
3 Reads

Sequencing of Chemotherapy and Radiotherapy for Newly Diagnosed Anaplastic Oligodendroglioma and Oligoastrocytoma.

Am J Clin Oncol 2019 Mar;42(3):258-264

Department of Radiation Oncology, Allegheny General Hospital, Pittsburgh, PA.

Introduction: Adjuvant management of anaplastic oligodendrogliomas (AOs) and anaplastic oligoastrocytomas (AOAs) is guided by 2 seminal phase III trials, one of which utilized radiotherapy (RT) followed by chemotherapy (CT) (RT-CT), and the other in which CT was followed by RT (CT-RT). Both paradigms are endorsed by the National Comprehensive Cancer Network because no direct comparison in the first-line (nonprogressive) setting has been performed to date. This study of a contemporary national database sought to evaluate practice patterns and outcomes between both approaches. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000511DOI Listing
March 2019
7 Reads

Factors Influencing Clinical and Setting Pathways After Discharge From an Acute Palliative/Supportive Care Unit.

Am J Clin Oncol 2019 Mar;42(3):265-269

Department of Sciences for Health Promotion and Mother Child Care, University of Palermo, Palermo, Italy.

Aim: The aim of this study was to assess the factors which influence the care pathway after discharge from an acute palliative supportive care unit (APSCU).

Methods: Patients' demographics, indications for admission, kind of admission, the presence of a caregiver, awareness of prognosis, data on anticancer treatments in the last 30 days, ongoing treatment (on/off or uncertain), the previous care setting, analgesic consumption, and duration of admission were recorded. The Edmonton Symptom Assessment Scale (ESAS) at admission and at time of discharge (or the day before death), CAGE (cut down, annoy, guilt, eye-opener), and the Memorial Delirium Assessment Scale (MDAS), were used. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000510DOI Listing
March 2019
3 Reads

Concurrent Radiosurgery and Immune Checkpoint Inhibition: Improving Regional Intracranial Control for Patients With Metastatic Melanoma.

Am J Clin Oncol 2019 Mar;42(3):253-257

Oregon Health & Science University, Portland, OR.

Objectives: The anti-CTLA-4 and antiprogrammed cell death-1 (PD-1) therapies have significantly improved survival of patients with metastatic melanoma. However, there is limited data regarding the interaction between immunotherapy (IT) and stereotactic radiosurgery (SRS) in patients with brain metastasis, particularly how combination therapy may affect toxicity and intracranial tumor control.

Methods: We retrospectively reviewed 26 patients with metastatic melanoma who received immune check point inhibitors and SRS for brain metastasis from 2011 to 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000509DOI Listing
March 2019
1 Read

Novel Immunotherapeutic Agents for the Treatment of Multiple Myeloma.

Am J Clin Oncol 2019 Mar;42(3):317-329

Division of Hematology/Oncology and GW Cancer Center, George Washington University School of Medicine and Health Sciences, Washington, DC.

Multiple myeloma (MM) is a B-cell malignancy characterized by the abnormal proliferation of clonal plasma cells in the bone marrow leading to end-organ manifestations. Despite the advancement in the therapy and care of patients with MM, relapse and resistance to standard therapy remain significant. The development of immunotherapy as a treatment modality for many types of cancers has led investigators to explore its use in MM in order to elicit myeloma-targeted immune responses, especially given that immune dysregulation is an underlying feature in the pathogenesis and progression of MM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000506DOI Listing
March 2019
8 Reads

Prospective Evaluation of Multinational Association of Supportive Care in Cancer Risk Index Score for Gynecologic Oncology Patients With Febrile Neutropenia.

Am J Clin Oncol 2019 Feb;42(2):138-142

Department of Obstetrics and Gynecology, Section of Gynecologic Oncology.

Background: The Multinational Association of Supportive Care of Cancer (MASCC) risk-index score has been validated as a stratification tool for febrile neutropenia (FN) risk in a heterogeneous group of cancer patients; recently, it has been deemed a suitable tool in gynecologic oncology patients in a retrospective study. This is a prospective multi-institutional study wherein we sought to validate MASCC score for stratifying FN morbidity in gynecologic oncology patients.

Methods: IRB approval was obtained at 4 institutions for prospective data collection of gynecologic cancer patients admitted with FN from 3/1/2013 to 9/1/2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000498DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345587PMC
February 2019
9 Reads

The Outcome of Patients With Localized Undifferentiated Pleomorphic Sarcoma of the Lower Extremity Treated at Stanford University.

Am J Clin Oncol 2019 Feb;42(2):166-171

Oncology.

Background: As a diagnosis of exclusion, Undifferentiated Pleomorphic Sarcoma (UPS) has unclear clinical characteristics. The objective of this retrospective cohort study is to investigate which clinical and prognostic factors of primary lower-extremity UPS will determine failure.

Methods: We retrospectively reviewed 55 primary lower-extremity UPS cases treated at Stanford between 1998 and 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000496DOI Listing
February 2019
2 Reads

Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma: A Single-Center, Open-Label, 2-Year Randomized Clinical Trial.

Am J Clin Oncol 2019 Feb;42(2):221-227

Division of Functional Neurosurgery, Institute of Psychiatry-IPq, Hospital das Clinicas, FMUSP.

Background: Complete tumor removal by transsphenoidal surgery is usually difficult for large nonfunctioning pituitary adenomas (NFPAs). A validated medical treatment may be useful for their management. This study evaluates the clinical efficacy of the dopaminergic agonist cabergoline for residual NFPA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000505DOI Listing
February 2019
1 Read

Identification of Adenosquamous Carcinoma as a Rare Aggressive HER2-negative Subgroup of Esophageal/Gastroesophageal Junction Adenocarcinoma.

Am J Clin Oncol 2019 Feb;42(2):190-195

Mayo Clinic, Rochester, MN.

Background: Our purpose was to evaluate the prognostic impact of pathologically confirmed esophageal adenosquamous carcinoma (ASC) and its association with HER2 status and clinicopathologic characteristics.

Methods: Among 796 patients with esophageal or gastroesophageal junction adenocarcinoma who underwent curative resection, surgical pathology reports were reviewed, and suspected ASC was confirmed utilizing p63 and CK5/6 immunostaining. HER2 status was determined using immunohistochemistry and fluorescence in situ hybridization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000495DOI Listing
February 2019
2 Reads

Concurrent Radiation and Immunotherapy: Survey of Practice Patterns in the United States.

Am J Clin Oncol 2019 Feb;42(2):208-214

Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD.

Objective: The objective of this study was to report on US radiation oncologists' (ROs) practice patterns and perceptions of concurrent radiation (RT) and immunotherapy (IT) (CRI).

Methods: A 22-question survey was emailed to radiation oncologists in February 2018. CRI was defined as RT completed within 1 week before initial IT infusion through 4 weeks after final IT infusion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000501DOI Listing
February 2019
16 Reads

Outcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced Pancreatic Cancer.

Am J Clin Oncol 2019 Feb;42(2):196-201

Department of Oncology, Virginia Mason Cancer Institute, Seattle, WA.

Objectives: There is limited randomized data to guide second-line chemotherapy selection in advanced pancreatic cancer (APC). We aimed to characterize predictors and outcomes of second-line chemotherapy in patients with APC.

Methods: We identified all patients with APC [locally advanced (LAPC) or metastatic (MPC)] who received ≥1 cycle of first-line chemotherapy between January 2012 and December 2015 across 6 cancer centers in British Columbia, Canada. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000500DOI Listing
February 2019
2 Reads
2.611 Impact Factor

Overall Survival of Men and Women With Breast Cancer According to Tumor Subtype: A Population-based Study.

Am J Clin Oncol 2019 Feb;42(2):215-220

Department of Medical Oncology, Breast Oncology Program, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

Objectives: To analyze differences in overall survival (OS) between male breast cancer (MBC) and female breast cancer (FBC) according to tumor subtype compared with other factors.

Materials And Methods: We evaluated men and women with breast cancer between 2010 and 2013 with known hormone receptor (HR) status and human epidermal growth factor receptor 2 (HER2) status reported to the National Cancer Institute's Surveillance, Epidemiology, and End Results program. Patient characteristics were compared between groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000497DOI Listing
February 2019
3 Reads

The Value of Prognostic Nutritional Index in Follicular Lymphoma.

Am J Clin Oncol 2019 Feb;42(2):202-207

Department of Clinical Oncology, Tuen Mun Hospital, New Territories West Cluster, Hong Kong.

Objectives: Previous studies reported that prognostic nutritional index (PNI), a marker of host inflammatory and nutritional status, is associated with prognoses in a number of cancer types. Thus, we investigated PNI at diagnosis as a prognostic factor in FL.

Methods: We reviewed FL patients in Tuen Mun Hospital, Hong Kong from 2000 to 2014 (n=88). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000493DOI Listing
February 2019
9 Reads